Guardant Health (NASDAQ:GH) Price Target Raised to $52.00

Guardant Health (NASDAQ:GH) had its price target increased by research analysts at Morgan Stanley from $42.00 to $52.00 in a note issued to investors on Thursday,Benzinga reports. The firm presently has an “overweight” rating on the stock. Morgan Stanley’s price target indicates a potential upside of 27.34% from the stock’s current price.

GH has been the subject of a number of other research reports. Raymond James reiterated an “outperform” rating and issued a $59.00 price target (up previously from $39.00) on shares of Guardant Health in a research note on Friday, February 21st. Stifel Nicolaus boosted their price target on Guardant Health from $45.00 to $53.00 and gave the stock a “buy” rating in a research report on Friday, February 21st. The Goldman Sachs Group lifted their price objective on shares of Guardant Health from $49.00 to $56.00 and gave the stock a “buy” rating in a research report on Friday, February 21st. Scotiabank boosted their price objective on Guardant Health from $47.00 to $52.00 and gave the stock a “sector outperform” rating in a report on Monday, February 24th. Finally, Guggenheim reaffirmed a “buy” rating and issued a $56.00 price objective on shares of Guardant Health in a report on Monday, February 24th. Twenty analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $48.40.

Guardant Health Trading Down 4.3 %

Shares of NASDAQ GH traded down $1.83 during mid-day trading on Thursday, hitting $40.83. The company had a trading volume of 665,963 shares, compared to its average volume of 2,444,771. Guardant Health has a one year low of $15.81 and a one year high of $50.89. The company has a market capitalization of $5.04 billion, a PE ratio of -11.53 and a beta of 1.50. The firm has a 50-day simple moving average of $41.70 and a two-hundred day simple moving average of $32.26.

Guardant Health (NASDAQ:GH) last posted its quarterly earnings results on Thursday, February 20th. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.15). The company had revenue of $201.81 million for the quarter, compared to analyst estimates of $192.50 million. Guardant Health had a negative return on equity of 19,157.20% and a negative net margin of 59.05%. Sell-side analysts expect that Guardant Health will post -2.9 earnings per share for the current fiscal year.

Insider Buying and Selling at Guardant Health

In other news, Director Musa Tariq sold 2,320 shares of Guardant Health stock in a transaction dated Friday, December 13th. The stock was sold at an average price of $35.00, for a total transaction of $81,200.00. Following the sale, the director now directly owns 2,676 shares of the company’s stock, valued at approximately $93,660. This trade represents a 46.44 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders have sold 2,668 shares of company stock worth $95,208 over the last quarter. Corporate insiders own 5.50% of the company’s stock.

Institutional Trading of Guardant Health

A number of institutional investors have recently bought and sold shares of GH. JNBA Financial Advisors purchased a new position in Guardant Health in the third quarter valued at approximately $26,000. R Squared Ltd bought a new stake in shares of Guardant Health in the fourth quarter valued at $26,000. Ashton Thomas Securities LLC purchased a new position in shares of Guardant Health during the 3rd quarter valued at $34,000. SBI Securities Co. Ltd. bought a new position in shares of Guardant Health during the 4th quarter worth $43,000. Finally, Kimelman & Baird LLC purchased a new stake in Guardant Health in the 4th quarter worth about $58,000. Institutional investors own 92.60% of the company’s stock.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.